Bepirovirsen posts phase III gains in hepatitis B cure push

Bepirovirsen advances a long-running effort to make hepatitis B treatment finite

New phase III data suggest the hepatitis B field may be moving closer to a practical definition of cure. According to results discussed in the New England Journal of Medicine and highlighted by University of Michigan Health hepatologist Anna S. Lok, about one in five patients in two duplicate clinical trials achieved a functional cure after 24 weeks of treatment with bepirovirsen. The placebo groups did not produce any functional cures.

That result matters because the standard approach to chronic hepatitis B is usually control rather than clearance. Nucleoside or nucleotide analog therapy can suppress viral replication and lower the risk of cirrhosis and liver cancer, but it rarely cures the infection. Many patients relapse if treatment stops before the loss of hepatitis B surface antigen.

The latest trials therefore stand out less as an incremental improvement in viral suppression and more as evidence that a finite course of therapy may be able to push a meaningful share of patients across a threshold the field has spent years trying to define. In 2016, regulators, liver-disease societies, academic researchers, and industry participants agreed that a functional cure should mean undetectable hepatitis B surface antigen and hepatitis B virus DNA at least 24 weeks after a finite treatment course ends. The new bepirovirsen data are framed against that benchmark.

What the trials found

The two phase III studies reported that 20% and 19% of patients achieved a functional cure after 24 weeks of bepirovirsen. Another notable finding was that 24% of patients taking the drug were able to discontinue nucleoside analog therapy, compared with none in the placebo groups. The report also said none of the patients who stopped nucleoside analog treatment, including some who did not meet the functional-cure endpoint, experienced clinical relapse during the follow-up described in the source material.

Those details are important because the clinical and commercial value of a hepatitis B breakthrough depends not only on improving laboratory markers, but also on reducing the need for indefinite maintenance therapy. A treatment that enables some patients to stop long-term antiviral drugs without immediate rebound would represent a meaningful change in care.

Why the result stands out

The hepatitis B cure field has been crowded with combinations of antiviral and immunomodulatory approaches for roughly a decade, yet the source text notes that only one phase III trial had been completed before these latest results. That makes the bepirovirsen studies notable not just for their outcome, but for their stage. Late-stage evidence carries more weight with clinicians, payers, and regulators than early proof-of-concept data.

Lok described the readout as a major step toward a functional cure, and the wording is measured. It does not suggest the virus has been eradicated in every treated patient, nor that existing standard therapy has been displaced. Instead, it points to a more practical milestone: finite treatment that can deliver durable control off therapy in a subset of patients.

That distinction matters in chronic viral disease. A “functional cure” is not the same as complete elimination of every trace of virus, but it can still be clinically transformative if it reduces relapse risk, lowers long-term complications, and changes how long patients must remain on therapy.

What comes next

The source material does not provide broader subgroup detail, durability beyond the reported follow-up, or a full safety profile, so the remaining questions are substantial. Physicians will want to know which patients benefited most, whether response rates can be improved, and how durable those responses remain over longer periods. Regulators and guideline writers will also need to weigh how the treatment fits alongside existing suppressive therapy.

Even with those open questions, the phase III outcome marks a genuine shift in tone for hepatitis B research. For years, the field has been defined by the gap between viral suppression and cure. Bepirovirsen has not closed that gap for everyone, but the new data indicate that the line separating chronic management from finite, potentially curative treatment may no longer be theoretical.

This article is based on reporting by Medical Xpress. Read the original article.